Compare OSUR & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSUR | STRO |
|---|---|---|
| Founded | 2000 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.2M | 85.0M |
| IPO Year | 1986 | 2018 |
| Metric | OSUR | STRO |
|---|---|---|
| Price | $2.43 | $10.46 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 8 |
| Target Price | $3.00 | ★ $18.29 |
| AVG Volume (30 Days) | ★ 659.3K | 122.9K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $125,703,000.00 | $105,646,000.00 |
| Revenue This Year | N/A | $63.08 |
| Revenue Next Year | $3.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.08 | $5.23 |
| 52 Week High | $4.22 | $21.50 |
| Indicator | OSUR | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 46.98 | 81.15 |
| Support Level | $2.41 | $8.49 |
| Resistance Level | $2.49 | $11.09 |
| Average True Range (ATR) | 0.10 | 0.83 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 27.12 | 89.41 |
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.